New hope for liver cancer patients after immunotherapy fails

NCT ID NCT07151326

First seen Nov 01, 2025 · Last updated May 11, 2026 · Updated 23 times

Summary

This study tests the drug cabozantinib in 60 adults with advanced liver cancer that worsened after initial immunotherapy. The goal is to see if cabozantinib can stop or slow tumor growth for at least 6 months. Researchers will also look for blood and tissue markers that predict response or resistance.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

Locations

  • Chang Gung Memorial Hospital (Lin-Kou),

    Taoyuan, Taiwan

    Contact

    Contact

  • Chang-Gung Memorial Hospital, Kaohsiung

    Kaohsiung City, Taiwan

    Contact

    Contact

  • China Medical University Hospital

    Taichung, Taiwan

  • Mackay Memorial Hospital

    Taipei, 104, Taiwan

    Contact

    Contact

  • National Cheng-Kung University Hospital

    Tainan, Taiwan

    Contact

    Contact

  • National Taiwan University Hospital

    Taipei, 100, Taiwan

    Contact

    Contact

  • Taichung Veterans General Hospital

    Taichung, 407, Taiwan

    Contact

    Contact

  • Taipei Veterans General Hospital

    Taipei, Taiwan

    Contact

    Contact

  • Tri-Service General Hospital

    Taipei, Taiwan

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.